Omadacycline tosylate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for omadacycline tosylate and what is the scope of patent protection?
Omadacycline tosylate
is the generic ingredient in one branded drug marketed by Paratek Pharms Inc and is included in two NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.Omadacycline tosylate has two hundred and fifty-one patent family members in forty countries.
One supplier is listed for this compound.
Summary for omadacycline tosylate
International Patents: | 251 |
US Patents: | 9 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 12 |
DailyMed Link: | omadacycline tosylate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for omadacycline tosylate
Generic Entry Dates for omadacycline tosylate*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW Dosage:
POWDER;INTRAVENOUS |
Generic Entry Dates for omadacycline tosylate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for omadacycline tosylate
Drug Class | Tetracycline-class Antibacterial |
Anatomical Therapeutic Chemical (ATC) Classes for omadacycline tosylate
US Patents and Regulatory Information for omadacycline tosylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | RX | Yes | Yes | 9,265,740 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | RX | Yes | Yes | 10,835,542 | ⤷ Subscribe | ⤷ Subscribe | ||||
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for omadacycline tosylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | 9,365,500 | ⤷ Subscribe |
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | 7,326,696 | ⤷ Subscribe |
Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | 7,326,696 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for omadacycline tosylate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Brazil | 0112269 | Composto de minociclina ou um seu sal farmaceuticamente aceitável, método para tratar um estado responsivo à tetraciclina em um mamìfero, composição farmacêutica, composto de minociclina 9-substituìda, e, método para tratar um estado responsivo à tetraciclina em um indivìduo | ⤷ Subscribe |
South Korea | 101893740 | ⤷ Subscribe | |
Brazil | 112019001948 | método de tratamento de um indivíduo humano. | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
Omadacycline tosylate Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.